Market Overview
The global multiple sclerosis market was valued at USD 25.0 billion in 2024 and is expected to grow at a CAGR of 5.0 % from 2025 to 2034. Growth is driven by increased healthcare expenditure and ongoing developments in disease-modifying therapies.
Geriatric medicines refer to pharmaceuticals and therapeutic formulations specifically designed for older adults (aged 65 and above), addressing conditions such as cardiovascular diseases, diabetes, arthritis, osteoporosis, neurological disorders, and other age-related ailments. Key market dynamics include:
- Aging Global Population: Life expectancy is increasing globally, while birth rates decline in many regions, expanding the elderly population.
- Rising Chronic Disease Burden: Older adults often face multiple chronic conditions, fueling demand for long-term therapies.
- Specialized Therapeutic Needs: Age-related changes in drug metabolism, polypharmacy risks, and the need for controlled-release or easy-to-swallow formulations drive innovation.
- Healthcare Infrastructure and Policies: Supportive government policies and increasing healthcare access enhance adoption of geriatric medicines.
Market Scope
The geriatric medicines market is broad, encompassing multiple segments:
- Therapeutic Categories: Includes analgesics, antihypertensives, antidiabetics, anticoagulants, antidepressants, and other drug classes tailored for older adults.
- Condition/Indication Segments: Covers cardiovascular diseases, diabetes and metabolic disorders, neurological disorders, osteoporosis/arthritis, and respiratory ailments.
- Distribution Channels: Medicines are delivered through hospital pharmacies, retail pharmacies, online platforms, and home-care delivery systems.
- Geographic Segments: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with growth driven by demographics, healthcare access, and regulatory support.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/global-multiple-sclerosis-market
Some of the major players operating include:
- Hoffmann-La Roche Ltd.
- Bayer Healthcare AG
- Teva Pharmaceuticals
- GlaxoSmithKline
- AbbVie Inc.
- Sonafi Pasteur
- Pfizer Inc.
- Merck & Company
- Novartis AG
- AB Science
- Opexa
Regional Analysis
- North America: The largest market due to high healthcare spending, advanced infrastructure, and aging population.
- Europe: Significant elderly population and strong healthcare policies support steady market growth.
- Asia-Pacific: The fastest-growing region due to increasing elderly populations, rising healthcare investments, and improved access.
- Latin America and Middle East/Africa: Emerging markets with potential for expansion as healthcare access improves.
Outlook
The Multiple Sclerosis market is expected to continue strong growth into the 2030s, driven by demographic trends and chronic disease prevalence. Challenges such as polypharmacy, safety concerns, regulatory hurdles, and pricing pressures exist, but opportunities from unmet medical needs, innovative formulations, and digital health integration are likely to sustain the market’s growth trajectory.
More Trending Latest Reports By Polaris Market Research:
Protein A, G, and L Resins Market
Unlocking Insights: Exploring the Urinalysis Market
Protein A, G, and L Resins Market
North America Metal Emblem And Logos Market
Rising Adoption of Sensor-based Devices to Drive Digital Patient Monitoring Devices Market
